Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
To the Editor: Dr Bridges and colleagues1 attempted to evaluate the economic costs and benefits of influenza vaccination among healthy workers in the United States using a sample of workers at a Ford Motors plant in Dearborn, Mich. It is not possible to conduct a cost-benefit analysis using the results of their study alone because the results of this study were not generalizable to the US population as a whole and because the sample size was too small to capture all relevant health events, such as hospitalizations or deaths. The authors' failure to include all relevant costs from representative data resulted in an inaccurate and incomplete tabulation of societal costs.
Muennig P. Influenza Vaccine for Healthy Working Adults. JAMA. 2001;285(3):290-292. doi:10.1001/jama.285.3.290